June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Therapeutic Effects of Paeoniflorin Following Retinal Ischemic-Reperfusion Injury
Author Affiliations & Notes
  • Crystal Su Algenio
    Ophthalmology , Loyola University Medical Center, Maywood, Illinois, United States
    Research Services, Edward Hines , Jr. VA Hospital, Hines, Illinois, United States
  • Mark Qiao
    Ophthalmology , Loyola University Medical Center, Maywood, Illinois, United States
  • Sabrina Chow
    Microbiology and Immunology , Loyola University Medical Center, Maywood, Illinois, United States
  • James F McDonnell
    Ophthalmology , Loyola University Medical Center, Maywood, Illinois, United States
  • Jay Perlman
    Ophthalmology/Pathology, Loyola University Medical Center, Maywood, Illinois, United States
    Surgery Service, Edward Hines, Jr. VA Hospital, Hines, Illinois, United States
  • Ping Bu
    Ophthalmology , Loyola University Medical Center, Maywood, Illinois, United States
    Research Services, Edward Hines , Jr. VA Hospital, Hines, Illinois, United States
  • Footnotes
    Commercial Relationships   Crystal Algenio, None; Mark Qiao, None; Sabrina Chow, None; James McDonnell, None; Jay Perlman, None; Ping Bu, None
  • Footnotes
    Support  Illinois Society for the Prevention of Blindness, The Richard A. Perritt Charitable Foundation
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5913. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Crystal Su Algenio, Mark Qiao, Sabrina Chow, James F McDonnell, Jay Perlman, Ping Bu; Therapeutic Effects of Paeoniflorin Following Retinal Ischemic-Reperfusion Injury. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5913.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinal ischemia-reperfusion presents a major common cause of visual impairment and blindness in the industrialized world. Current treatment options for retinal ischemic diseases are very limited. Paeoniflorin is a monoterpene glycoside derived from the root of Paeonia lactiflora Pallas. Paeoniflorin has been shown in previous studies to exhibit various pharmacological properties including anti-inflammatory, antioxidant, and immunoregulatory activities, making it a potential therapeutic agent against degenerative pathologies. The purpose of this study is to determine if Paeoniflorin attenuates retinal degeneration by minimizing oxidative and inflammatory stress in retinal ischemic-reperfusion injury.

Methods : C57BL/6 mice were assigned to one of two groups: vehicle- treated or Paeoniflorin-treated retinal ischemic injury mice. Retinal ischemia was induced by transient elevation of intraocular pressure for 45 minutes. Vehicle (PBS) or Paeoniflorin (20 mg/kg in PBS) was injected intraperitoneally once a day for 5 days following retinal ischemia. Scotopic electroretinography (ERG) was recorded before induction of retinal ischemia, and 7 days after inducing ischemia. The amplitude and times of the scotopic a- and b-waves were quantified and statistically compared among Paeoniflorin treatment and control groups.

Results : Before treatment, scotopic ERG a- and b-wave amplitudes were 392 ± 75 μV and 831 ± 62 μV, respectively, in the control group, and 396 ± 43 μV and 818 ± 75 μV, respectively, in the Paeoniflorin group. Following ischemic-reperfusion injury, ERG a-wave amplitudes were 180 ± 13 μV in the control group and 307 ± 61 μV in the Paeoniflorin group (p < 0.005). Post-ischemic insult ERG b- wave amplitudes were 320 ± 48 μV in the control group and 583 ± 74 μV in the Paeoniflorin group (p < 0.005). Seven days after ischemic-reperfusion injury, Paeoniflorin treatment of mice was proven to attenuate ischemic induced loss of retinal function compared to vehicle treated mice, as shown by the preservation of ERG a- and b-wave amplitudes.

Conclusions : Conclusions: Paeoniflorin treatment of mice showed attenuation of retinal degeneration by preservation of ERG a-and b-wave amplitudes following ischemic-reperfusion injury. Our preliminary data suggests that Paeoniflorin may have therapeutic value in the management of retinal ischemic diseases.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×